home / stock / prqr / prqr news


PRQR News and Press, ProQR Therapeutics N.V. From 02/24/22

Stock Information

Company Name: ProQR Therapeutics N.V.
Stock Symbol: PRQR
Market: NASDAQ
Website: proqr.com

Menu

PRQR PRQR Quote PRQR Short PRQR News PRQR Articles PRQR Message Board
Get PRQR Alerts

News, Short Squeeze, Breakout and More Instantly...

PRQR - ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

Additional analyses ongoing from Phase 2/3 Illuminate trial of sepofarsen in LCA10 with updates on any potential next steps with this program and overall strategy anticipated in Q2 2022 Phase 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome ...

PRQR - Why ProQR Therapeutics Stock Got Slammed Again Monday

For the second trading day in a row, investors sold off shares of ProQR Therapeutics (NASDAQ: PRQR) . The clinical-stage biotech's shares were hit by a series of analyst downgrades and price target cuts in the wake of the company's latest report about a once-promising drug candidate...

PRQR - ProQR cut to Neutral at Citi after "puzzling" trial results for RNA therapy

Citi has downgraded ProQR Therapeutics (PRQR -78.2%) to Neutral from Buy after the clinical-stage biotech company reported that its pivotal Phase 2/3 study for RNA therapy sepofarsen did not meet the main goal in Leber congenital amaurosis 10 (LCA10). After more than ~75% decline in valu...

PRQR - Why ProQR Therapeutics Is Crashing Today

Shares of ProQR Therapeutics (NASDAQ: PRQR) , a clinical-stage biopharmaceutical company, are sinking in response to lousy clinical trial results. The company's lead candidate, sepofarsen, failed to meet the primary endpoint in the Illuminate study. The stock was down 75.1% as of 12...

PRQR - CRS, COE, YMAB among mid-day gainers

Gainers: Kaival Brands Innovations KAVL +42%. Y-mAbs Therapeutics YMAB +29%. China Online Education (NYSE:COE) +24%. Mr. Cooper COOP +20%. Zillow Z +19%. Carpenter Technology (NYSE:CRS) +19% Zillow ZG +18%. Eqonex EQOS +17%. Bloom Energy BE +17%. XPEL (...

PRQR - Orphazyme, Y-mAbs Therapeutics top healthcare gainers; ProQR, Senseonics lead losers pack

Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%.  Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...

PRQR - Affirm Holdings, Cleveland-Cliffs, The Chemours among premarket losers' pack

ProQR Therapeutics (NASDAQ:PRQR) -69% after the trial for sepofarsen in Leber congenital amaurosis did not meet main goal. Betterware de Mexico (NASDAQ:BWMX) -26% on Q4 earnings release. Hudson Capital (NASDAQ:HUSN) -13%. PetVivo Holdings (NASDAQ:PETV) -18% on&#x...

PRQR - ProQR says trial for sepofarsen in Leber congenital amaurosis did not meet main goal

ProQR Therapeutics (NASDAQ:PRQR) announced on Friday that the company’s pivotal Phase 2/3 Illuminate trial for RNA therapy sepofarsen in EP290-mediated Leber congenital amaurosis 10 (LCA10) did not meet the primary endpoint of Best Corrected Visual Acuity (BCVA). ProQR (PRQR) is curren...

PRQR - ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

Study did not meet primary endpoint nor notable secondary endpoints – no benefit observed in either treatment arm versus sham Additional analyses to be conducted and presented at a future medical congress Sepofarsen continues to be generally well tolerated Strong cash p...

PRQR - ProQR to Present at Upcoming SVB Leerink Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Compa...

Previous 10 Next 10